Susannah Gray - Feb 26, 2023 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
Director
Signature
/s/ Brett A. Grimaud, Attorney-in-Fact
Stock symbol
TBPH
Transactions as of
Feb 26, 2023
Transactions value $
$0
Form type
4
Date filed
2/28/2023, 07:17 PM
Previous filing
Jun 10, 2022
Next filing
May 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Award $0 +10.1K $0.00 10.1K Feb 26, 2023 Direct
transaction TBPH Ordinary Shares Award $0 +1.69K +16.66% $0.00 11.8K Feb 26, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TBPH Share Option (Right to Buy) Award $0 +28K $0.00 28K Feb 26, 2023 Ordinary Shares 28K $9.87 Direct F1
transaction TBPH Share Option (Right to Buy) Award $0 +4.67K $0.00 4.67K Feb 26, 2023 Ordinary Shares 4.67K $9.87 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests monthly over 24 months of service from the date of grant.
F2 This option shall vest monthly over two months of service from the date of grant and will vest in full upon earlier of the two-month anniversary of Susannah Gray's appointment to the Board or the date of Company's 2023 annual meeting of Shareholders.